Investigation by Parkinson's disease research group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: Further results of randomised trial and confidential inquiry

British Medical Journal

Volumn 316, Issue 7139, 1998, Pages 1191-1196

  Ben Shlomo, Y ^a   Churchyard, A ^b   Head, J ^d   Hurwitz, B ^e   Overstall, P ^f   Ockelford, J ^c   Lees, A J ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f WYE VALLEY NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPA DECARBOXYLASE INHIBITOR; LEVODOPA; SELEGILINE;

ARTICLE; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR EFFECT; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DRUG FATALITY; FALLING; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

EID: 0032542955     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.316.7139.1191     Document Type: Article

References (24)

1. Lees AJ. on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinsons disease. BMJ 1995;311:1602-7.
2. Parkinson's Disease Research Group of the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three years interim report. BMJ 1993;307:169-72.
3. Tatlon WG, Greenwood CE. Rescue of dying neurones: a new action for deprenyl in MPTP parkinsonism. J Neurol Sci 1991;30:666-72.
4. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-71.
5. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased lile expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 1985;64:113-27.
6. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson's disease. Ann Neurol 1996;40:841-5.
7. Silva M, Watts P, Jenner P. Effect of adding selegiline to levodopa in early, mild Parkinson's disease: Parkinson's disease is rarely a primary cause of death. BMJ 1996;312:703.
8. Jellinger KA. Effect of adding selegiline to levodopa in early, mild Parkinson's disease: causes of death need confirmation. BMJ 1996;312:704.
9. Gerlach M, Riederer P, Vogt H. Effect of adding selegiline to levodopa in early, mild Parkinson's disease: 'on treatment' rather than intention to treat analysis should have been used. BMJ 1996;312-704.
10. Lees AJ, Head J, Ben-Shlomo Y. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. BMJ 1996;312:701-5.
11. Lees AJ, Head J, Ben-Shlomo T. Selegiline and mortality in Parkinson's disease: another view. Ann. Neurol 1997;41:282-3.
12. World Health Organisation. Manual of the international classification of diseases, injuries, and causes of death, 9th revision. Geneva: World Health Organisation, 1978.
13. Alderson MR, Meade TW. Accuracy of diagnosis on death certificates compared with that in hospital records. Br J Prev Soc Med 1967;21:22-9.
14. Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994.
15. Fleiss JL. The measurement of interrater agreement. In: Fleiss JL, ed. Statistical methods for rates and proportions, 1st ed. New York: Wiley, 1981:212-36.
16. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991;18:275-8.
17. Wenning GK, Ben-Shlomo Y, Magalhes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117:835-45.
18. Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiat 1996;60:615-20.
19. Turkka J, Suominen K, Tolonen U, Sontaniemi K, Myttyla VV. Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease. Neurology 1997;48:662-7.
20. Churchyard A, Matthias CJ, Boonhongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:228-34.
21. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-22.
22. Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet 1981;1:1262-5.
23. Ben-Shlomo Y, Whitehead AS, Davey Smith G, Parkinson's, Alzheimer's and motor neurone disease: clinical and pathological overlap may suggest common genetic and environmental factors. BMJ 1996;312:724.
24. Campbell AJ, Buchner DM. Unstable disability and fluctuation of frailty. Age Ageing 1997;26:315.